🔗 Share this article

While America continues making unprecedented adjustments to its immunization guidelines, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by casting doubt on COVID-19 shots throughout the pandemic and has focused upon possible fatalities following COVID-19 vaccination in her brief position at the FDA.

Proposed Overhauls to Childhood Vaccine Schedule

Agency leaders had intended to reveal sweeping revisions to the childhood vaccine schedule in December, bringing the US with the Danish immunization schedule, it is understood – a substantial departure that would place the US at odds with much of the international standard with little proof for benefit. The announcement has been postponed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was recently named temporary leader of the FDA’s CDER, the fifth person to run the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it points to a greater focus upon reevaluating already-approved immunizations at the FDA.

The new acting director has frequently advocated for halting certain childhood vaccine recommendations in the US to become more like the Danish model, a society with nationalized medicine and a citizenry about the size of Wisconsin’s.

So far comments, she has continued to focus on immunizations – typically the domain of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Qualifications

Dr. Høeg has no obvious background in pharmaceutical research, approval processes or leadership, which has been customary for former leaders of the CBER. She has worked at the FDA as a key advisor to the FDA chief and CBER since March.

“She appears not to have the requisite experience” for running the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in managing a major agency. She has no expertise in drug approvals.”

Previous commissioners of the center would “understand legal statutes and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that prior appointees who ran the center have had.”

CDER has an enormous portfolio at the FDA, she pointed out.

“The public just focuses on the innovative therapies, but the generic program authorizes a multitude of generic medications. There’s a biosimilars division, over-the-counter program and more, and each of these must be looked after,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

There is also, a significant management aspect to the role, which oversees more than 5,000 employees. “It is a huge management job, if you execute it properly,” the former official said.

Agency Reaction and Disputed Initiatives

Regarding questions about Høeg’s credentials and whether this assignment signifies greater collaboration among agency officials on vaccines, a representative said that the “concerns rely on flawed presumptions”.

“This background aligns with the duties of her position,” the spokesperson explained, noting the time Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg takes over the commissioner’s controversial fast-track approval initiative, a contentious expedited drug-approval program that apparently worried her preceding directors. “By what process are these medications being chosen for this expedited pathway? Who takes the choices?” Howard said. “There’s a lot of lack of transparency occurring at the FDA right now.”

Broadly speaking, he stated, “the agency appears to be shifting towards less stringent oversight of most medications, with the exception of vaccines.”

Established History on Vaccines

Concerning immunizations, Høeg has a more documented, if concerning, past, critics have noted. She authored a study using unverified crowd-sourced reports to assess the incidence of heart inflammation after COVID-19 immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Part of her “wish list” for the new administration encompassed revising regulations for novel immunizations and halting “non-essential” vaccines, she remarked after the election on a audio program. At the FDA, Dr. Høeg has according to sources suggested excluding teenage boys from receiving COVID-19 vaccines.

“She is an thorough ideologue who commences with her beliefs and reverse-engineers to accommodate the science in a extremely misleading, dishonest fashion,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Høeg joined other contrarians, {like|